Skip to main content
Fig. 3 | Cancer Cell International

Fig. 3

From: Proteo-transcriptomics meta-analysis identifies SUMO2 as a promising target in glioblastoma multiforme therapeutics

Fig. 3

SUMO2 is a promising drug target for both adult and pediatric glioblastomas: A, B, C Microarray data from molecularly sub-typed (GEO-GSE118793) glioblastoma tumour tissues, the freshly isolated tumour cells from these sub-typed tumours and the orthotropic xenografts generated from the isolated tumours cells showed fidelity in high SUMO2 expression across classical, mesenchymal and proneural GBMs. D Pediatric Brain Atlas-CBTTC platform microarray data analysis from pediatric low and high-grade glioma tissues confirms high SUMO2 expression vs other SUMO isoforms. E, F, G Microarray data from pediatric glioblastoma (GBM, astrocytoma Grade IV; GEO-GSE99961) and astrocytomas (Grade II–III) tumour tissues, the freshly isolated tumour cells from these pediatric tumour grades, and the orthotropic xenografts generated from the isolated tumours cells showed fidelity in high SUMO2 expression. PDOX refers to Pediatric Orthotropic Xenografts; PBT refers to Pediatric Brian Tumours or astrocytomas between grades III-II. GBM is Grade IV astrocytoma. H CRISPR/CAS gene knockout based pan-cancer dependency test for SUMO2 in cancer cell survival fitness was extracted from DepMAP portal (https://depmap.org/portal/). The values in the table shows that 789 cancer cell lines were included in the study, wherein only SUMO2 isoform showed up as a common essential gene for the overall survival of cancer cells. I The schematic representation sums up the findings in this study which suggest that SUMO2 isoform by itself may be a key player in GBM development and progression via exercising its control on the genes involved in the hallmarks of cancer. Hence, SUMO2 is a promising target for anti-GBM therapeutics in all GBM subtypes. All datasets are reported as mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001 and ****p < 0.0001; Mean is derived from a statistically significant number of samples except in panels E, F, G and Student t-test function was used to drive significance. For in-depth details on individual data points and dataset sample size in each graph, please refer to corresponding additional tables mentioned in the main manuscript text

Back to article page